We offer a wide range of formulation development services, from preclinical formulation to developing and manufacturing first-in-human clinical supplies to commercial supplies. We have expertise in developing all major dosage forms including oral solids, parenteral and topical dosage forms.
Our commercial manufacturing facilities mainly cover potent and non-potent oral solids, oral liquids, topicals, nasal sprays and soft gelatin capsules . Our manufacturing facilities are audited by major regulatory agencies.
Pre-formulation
Our preformulation studies cover the assessment of a wide range of physical and chemical properties, which are critical to design the formulation and delivery method for your lead candidates. Once the drug properties are studied, our team of experts can help arrive at the right formulation that meets the necessary regulatory guidelines.
Early-phase Formulation
Our early-phase formulation development services help solve oral bioavailability challenges encountered at both preclinical formulation development and clinical formulation development stages. We can address following issues through in-depth solubilization and enabling various technologies:
- Incomplete dissolution
- Low solubility
- Low oral bioavailability
Our services for discovery phase formulation development are tailored to address specific challenges which arise due to:
- Higher systemic exposure requirements for toxicology studies
- Non-feasibility of high doses or strengths
- Studies in varied animal species
- Emesis
- Compound limitation
- Liquid dosage form requirement
- Precipitation of compound at absorption site
Formulation Development
We offer formulation development services from GLP-compliant and cGMP environment to meet client requirements. Our formulation development services can help in translating new drug candidates into drug products for your clinical trial needs.
Our formulation development services include:
- Preclinical (Oral- Solution, suspensions and microdose capsules, Parenterals- aqueous liquid injectables, non-aqueous injectables, lyophilized injectables, ophthalmic and otic solutions and nasal solutions)
- First in human formulations (Oral Solids, Parenterals)
- Clinical formulations (Oral solids, soft gelatin capsules and parenterals-aqueous liquid injectables, non-aqueous injectables, lyophilized injectables, ophthalmic and otic solutions and nasal solutions)
Characterization Studies
We conduct all characterization studies in-house. Dissolution testing is a requirement for solid oral dosage forms throughout the development life cycle and commercial manufacturing. Our services help understand the process in which a substance forms a solution and measure the extent and rate of solution formation from a dosage form, such as a tablet, capsule, and ointment.
Our characterization services for NCEs, generics and first generics help assess the quality characteristics of drug products such as physical and chemical properties, which are primary elements to ensure the desired quality, considering the safety and efficacy of the drug product.
We help to understand physical, chemical, biological, and microbiological properties or characteristics that should be within an appropriate specification to ensure the desired product quality.
The potential physical and chemical interactions between drugs and excipients can affect the dosage form's chemical, physical, and therapeutic properties, and stability. Drug excipient compatibility studies are an important part of understanding the role of inactive ingredients (excipients) in product quality and performance. Our mechanistic understanding of the drug substance and its impurities, excipients, and impurities, degradation pathway, and potential processing conditions helps select the right excipients for the compatibility study.
Pharmaceutical Stability Studies
We help our clients understand the stability and quality of drug substances (API) and drug products (finished formulation) against different environmental factors such as temperature, humidity, and light. Our stability testing services are offered by ICH guidelines. They include the study of product-related factors that influence the quality of a drug, such as the interaction of an API with excipients, container closure systems, and packaging materials but also the proneness to oxidation and hydrolysis.
Clinical Supplies
We manufacture clinical formulations from our USFDA-inspected sites based out of Hyderabad and Visakhapatnam, India. We can cater to manufacture oral solids as well as soft gelatin formulations.
Why Aurigene Pharmaceutical Services?
Services from early formulation to clinical manufacturing
Integrated API and formulation capabilities
Experience with advanced formulation technologies
Integration with biology services for in vitro and in vivo studies
Global accreditations
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Drug Formulation Services
Contact Us
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.